rBCG-LTAK63 enhances protection against tuberculosis by inducing autophagy and circadian gene regulation
Tuberculosis (TB) remains a global public health challenge, with the current BCG vaccine providing limited efficacy in adults, and available treatments being lengthy and debilitating. To overcome these challenges, we have previously developed a recombinant BCG strain expressing the detoxified <i>E. coli</i> Heat-Labile Toxin (LTAK63), providing increased protection in mouse models and reduced lung pathology. Here, using systems biology and RNA sequencing of lung tissues in a murine model, we uncover the molecular mechanisms underlying rBCG-LTAK63's increased protection. Immunization triggered early activation of cAMP-related pathways, leading to hypoxia, autophagy, and circadian rhythm gene regulation. These processes were associated with an enhanced innate immunity and promoted long-lasting Th1/Th17 adaptive responses. Upon challenge, mice immunized with rBCG-LTAK63 exhibited an earlier onset of interferon-gamma response, reduced bacterial burden, and improved lung histopathology. Notably, circadian rhythm regulation was directly linked to a controlled inflammatory response and reduced migration of infection-susceptible cells, resulting in decreased immunopathology. Our findings demonstrate that rBCG-LTAK63 orchestrates protection through the integration of metabolic and temporal immune pathways. This work provides mechanistic insights into how rational vaccine design can reprogram host immunity to enhance protection and reduce pathology, supporting rBCG-LTAK63 as a promising next-generation TB vaccine candidate.
Authors
- Silas Fernandes Eto (ORCID: https://orcid.org/0000-0003-4796-9727)
- Sergio Verjovski‐Almeida (ORCID: https://orcid.org/0000-0002-6356-2401)
- Monalisa Martins Trentini (ORCID: https://orcid.org/0000-0002-3207-8967)
- André Guilherme Costa Martins
- Armando Carvalho (ORCID: https://orcid.org/0000-0003-2455-8781)
- Helder I. Nakaya (ORCID: https://orcid.org/0000-0001-5297-9108)
- Leonardo Paiva Farias (ORCID: https://orcid.org/0000-0002-4909-5333)
- Ana Marisa Chudzinski‐Tavassi (ORCID: https://orcid.org/0000-0001-7717-7013)
- Aldo Tagliabue
- Murilo Sena Amaral (ORCID: https://orcid.org/0000-0003-4999-5099)
- Ana Carolina Ramos Moreno (ORCID: https://orcid.org/0000-0002-3024-8045)
- Diana Boraschi (ORCID: https://orcid.org/0000-0002-3953-4056)
- Pablo Ivan Pereira Ramos (ORCID: https://orcid.org/0000-0002-9075-7861)
- Alex I. Kanno (ORCID: https://orcid.org/0000-0002-4731-1493)
- Aristóteles Passos Araújo Neto (ORCID: https://orcid.org/0000-0003-3182-7425)
- Lázaro Moreira Marques Neto (ORCID: https://orcid.org/0000-0003-0760-0044)
- André N. A. Gonçalves (ORCID: https://orcid.org/0000-0001-5264-8368)
- Luciana C. C. Leite (ORCID: https://orcid.org/0000-0003-0156-1312)
Institutions
- Universidade de São Paulo (BR)
- Hospital Israelita Albert Einstein (BR)
- Instituto Butantan (BR)
- Microsoft (Brazil) (BR)
- Shenzhen Institutes of Advanced Technology (CN)
- Fleury S.A. (Brazil) (BR)
- Shenzhen Technology University (CN)
- Fundação Oswaldo Cruz (BR)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-10-24
- DOI
- https://doi.org/10.3389/fimmu.2025.1695560
- Citations
- 1
- Primary Topic
- Epigenetics and DNA Methylation
- Type
- article
- Field-Weighted Citation Impact
- 0.81